2nd CRISPR-Based Therapy Analytical Development Summit
Evvnt Promotion / evvnt
17.09.2024 - 19.09.2024 Hilton Boston Logan Airport, One Hotel Drive, 02128 Boston, Massachusetts, USA
Time: 9:00 AM - 5:00 PM
Conference themes
As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.
As CRISPR-based therapies become ever complex, drug developers urgently need to innovate the analytical tools available to effectively characterize their safety and efficacy profiles and agree upon gold standards moving forward. We are also witnessing increased regulatory scrutiny, with the FDA closely studying off-target analysis conducted ahead of the approval of Casgevy, prior to finalizing guidance on genome editing therapies in January.
Professional congress organizer (PCO)
Hanson Wade
Hanson Wade
Notes
URL:
Brochure: https://go.evvnt.com/2433843-3?pid=4832
Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, and more
URL:
Brochure: https://go.evvnt.com/2433843-3?pid=4832
Speakers: Andrew Kernytsky, Principal Consultant, Next Gen Editing, Bryant Chia, Scientist, Analytical Chemistry and Structural Biology, Editas Medicine, and more
Enquiries and Registration:
https://go.evvnt.com/2433843-2?pid=4832
Ms. Jasmine Fletcher
General Medicine
Organizer contact info
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International promotes access to education and training for all regardless of social, geographic and national borders."
